含培美曲塞联合方案治疗原发性中枢神经系统淋巴瘤的疗效  

Efficacy of pemetrexed-contained regimens for primary central nervous system lymphoma

作　　者：尹美凤 张旭东[1] 马咪静 王欣 胡俊霞 吴少璇 杨万秋 王进隆 薛伍君 朱利楠[1] 牛松涛[1] 丁梦杰[1] 董萌[1] 吴晶晶[1] 张明智[1] 陈清江[1] YIN Meifeng;ZHANG Xudong;MA Mijing;WANG Xin;HU Junxia;WU Shaoxuan;YANG Wanqiu;WANG Jinlong;XUE Wujun;ZHU Linan;NIU Songtao;DING Mengjie;DONG Meng;WU Jingjing;ZHANG Mingzhi;CHEN Qingjiang(Department of Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052;Department of Oncology,the Third Affiliated Hospital,Xinxiang Medical College,Xinxiang,Henan 453003)

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052 [2]新乡医学院第三附属医院肿瘤科,河南新乡453003

出　　处：《郑州大学学报（医学版）》2020年第1期86-89,共4页Journal of Zhengzhou University(Medical Sciences)

基　　金：国家自然科学基金青年项目(81700187)

摘　　要：目的:探讨含培美曲塞(PEM)联合方案治疗原发性中枢神经系统淋巴瘤(PCNSL)的有效性和安全性。方法:收集16例中枢神经系统淋巴瘤患者的资料,其中7例已接受一线方案化疗后复发,9例为初治患者。化疗方案为PEM 600 mg/m 2静脉滴注,第1天;联合伊达比星(IDA)和地塞米松(DXM),或福莫司汀(FTM)和DXM,或替莫唑胺(TMZ)和DXM。结果:7例复发难治患者均完成至少2个周期的化疗,部分缓解(PR)3例,稳定(SD)3例,病情进展(PD)1例(该例死亡)。9例初治患者均完成至少4个周期的化疗,完全缓解1例,PR4例,SD3例,PD1例。主要不良反应为骨髓抑制,无因严重不良反应导致停药者,患者耐受性好。结论:含PEM联合方案对于PCNSL具有较好安全性和临床治疗活性。Aim:To summarize the efficacy and safety of pemetrexed(PEM)-contained regimens in the treatment of primary central nervous system lymphoma(PCNSL).Methods:The data of 16 patients with PCNSL were collected.Among them,7 patients had relapsed after first-line chemotherapy,and 9 patients were primary patients.The chemotherapy regimen was PEM 600 mg/m 2 intravenous drip on the first day,combined with IDA and DXM,or FTM and DXM,or TMZ and DXM.Results:Seven patients with refractory relapse completed at least 2 cycles of chemotherapy,3 patients with partial remission(PR),3 patients with stable(SD),and 1 patient with progression(PD).All the 9 primary patients completed at least 4 cycles of chemotherapy,1 case with complete remission,4 cases of PR,3 cases of SD,1 case of PD.The main adverse reaction was myelosuppression.No serious adverse reaction resulted in drug withdrawal,and the patients had good tolerance.Conclusions:PEM-contained regimens for PCNSL have clinical efficacy with safety.

关 键 词：中枢神经系统淋巴瘤 培美曲塞 大剂量化疗 

分 类 号：R733.4[医药卫生—肿瘤]